Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma

Authors:

Abstract
SUMMARYBackground: Current asthma guidelines recommend that patients are educated to adjust their medication according to their asthma severity using physician-guided self-management plans. However, many patients take a fixed dose of their controller medication and adjust their reliever medication according to asthma symptoms.Objectives: This study examined whether asthma control improved if patients adjusted the maintenance dose of budesonide/formoterol (Symbicort Turbuhaler 160/4.5 |ig) according to asthma severity compared with traditional fixed dosing (FD) regimens. * Symbicort and Turbuhaler are registered trademarks owned by the AstraZeneca group, t Seretide and Diskus are trademarks of GlaxoSmithKline.Methods: Symptomatic patients with asthma (n = 658, mean symptom score 1.5, mean inhaled corticosteroids 735|ig/day, mean forced expiratory volume in 1 second [FEV1] 84% predicted) were randomised after 2 weeks' run-in to either: budesonide/formoterol adjustable maintenance dosing (AMD), budesonide/fo...

This publication has 21 references indexed in Scilit: